TEPKINLY 4 mg/0,8 mL, solution injectable

( ARTG ) EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.‍‍‍‍‍‍​​​‍​​​​​​ EPKINLY is not indicated for the treatment of patients with primary central nervous system lymphoma. This medicine has provisional approval in Australia for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. The decision to approve this indication has been made on the basis of overall response and duration of response from an uncontrolled, open label phase I/II study. Continued approval of this indication depends on verification and description of benefit in confirmatory trials.